## Immune Globulins (Ig) Enrollment Form



Phone: 1-866-899-1661



	Six	Simple Step	s to Submittin	ıq a Referra	al			
1 PATIENT INFORM								
Patient Name:				Cit	v. State, ZIP:			
Preferred Contact Metho	ds: Phone (to primar	v # provided be	low)  Text (to	cell # provide	ed below) $\square$ Email (t	o email provided	below)	
Note: Carrier charges ma							,	
Primary Phone:							;	
Email:		Last Four of	f SSN:	Pı	imary Language:			
2 PRESCRIBER INF								
			State License	#:				
Prescriber's Name: NPI #:	DEA #:	Group or H	Hospital:					
Address:		<del></del> '	City, State, Z	IP:				
Address:Phone:	Fax	Coi	ntact Person:		Contact's Pho	ne:		
3 INSURANCE INFO	DRMATION Please fa	ax copy of presc	ription and insur	ance cards v	—— vith this form, if availa	able (front and ba	ck)	
Insurance Company: _			·			•	,	
4 DIAGNOSIS AND								
Needs by Date:			er:					
Service Location:		_						
☐ Home or Coram AIC	Diluents, Flushes, Su	pplies, Nursing	Services for dru	g administrat	ion/therapy teach tra	in		
	Drug Only for facility a							
Diagnosis (ICD-10):								
C91.10 Chronic lymph	nocytic leukemia of B-ce	ell type not havir	ng achieved rem	ission				
☐ D69.3 Immune thromb	D80.0 Conge	nital Hypogaı	mmaglobulinemia					
<ul><li>☐ D69.3 Immune thrombocytopenic purpura</li><li>☐ D80.2 Selective deficiency of IgA</li></ul>			☐ D80.3 Selective deficiency of IgG subclasses					
☐ D80.4 Selective deficiency of IgM ☐ D80.5 Immunodeficiency with increased IgM								
☐ D80.6 Antibody deficie	ency with near-normal Ir	mmunoglobulins	s or with hyperim	nmunoglobuli	nemia			
☐ D80.7 Transient hypogammaglobulinemia ☐ D81.0 SCID with reticular dysgen					dysgenesis			
☐ D81.2 SCID with low or normal B cell numbers			☐ D81.5 Purine nucleoside phosphorylase deficiency					
☐ D81.6 Major histocompatibility complex class I			☐ D81.7 Major histocompatibility complex class II					
☐ D81.89 Other combined immunodeficiencies			☐ D81.9 SCID (Unspecified)					
☐ D82.0 Wiskott-Aldrich syndrome			☐ D82.1 De George's syndrome					
☐ D82.4 Hyperimmunog	lobuin E syndrome							
☐ D83.0 Common Variable Immunodeficiency with Predominant abnormalities of B cell numbers and function								
☐ D83.1 Common Variable Immunodeficiency with predominant Immunoregulatory T cell disorders								
☐ D83.2 Common Varia	_		ies to B or T cell	s				
☐ D83.9 Common Varia		unspecified						
☐ G11.3 Cerebellar atax	ia with defective DNA		☐ G35 MS (Rela		ting)			
☐ G61.0 GBS		[	☐ G61.81 CIDP					
☐ G61.89 MMN			G70.00 MG w		exacerbation			
G70.01 MG with acute exacerbation			M33.20 Polyn					
M33.90 Dermatomyositis			Other Code: Description:					
For additional ICD-10 info	•	•			<u>ite</u>			
https://www.cvsspecialty.		y/healthcare-pr	ofessionals/abou	ut-us				
Patient Clinical Informa	<u>tion:</u>							
Allergies/rxn:				Height:	in/cm	Weight:	lb/kg	
History of: Headache								
First time receiving Immu			f first dose, plea					
If No, previous product us	sed:	L	_ast dose given:		Next dose due	e:		

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received

this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. ©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-35800A 040620

## Immune Globulins (Ig) Enrollment Form

Deticat Nesses		Please complete Patient and Prescriber in	formation		
Patient Name:		Patient DOB:			
Prescriber Name:					
☐ Asceniv 10% ☐ Bivigam 10% ☐ Cuvitru 20% (SC route ☐ Gamastan (IM route)		MATION       Select One Immune Globulin Product:         Gammagard Liq 10%       ☐ Gamunex-C 10         Gammagard S/D ☐ 5% ☐ 10%       ☐ Hizentra 20% (S         Gammaked 10%       ☐ HyQvia 10% (S         Gammaplex ☐ 5% ☐ 10%       ☐ Octagam ☐ 58			
		rams 🗌 mg/kg (dose will be rounded to the nearest vial			
<b>Directions:</b> ☐ Daily x	Day (s)	, everyWeek	infuse over hours		
		n rate directions			
		for administration			
· · · · · · · · · · · · · · · · · · ·	_	nome if pharmacy deems appropriate	•		
	dose in the i	юте и рнатнасу честь арргорнате			
Lab Orders:		W = 110 1 110 1 110 1 1 1 1 1 1 1 1 1 1 1			
MEDICATION	ROUTE	W THIS LINE WILL ONLY BE SENT FOR INFUSIONS DOSE /STRENGTH	DIRECTIONS		
MEDICATION	KOUTE	DOSE/STRENGTH	Catheter Care/Flush – Only on IG drug admin days		
Catheter: □ PIV □ PORT □ PICC	IV	NA	<ul> <li>SASH or PRN to maintain IV access and patency</li> <li>PIV – NS 5mL (Heparin 10 units/mL 3-5mL if multiple days)</li> <li>PORT/PICC – NS 10mL &amp; Heparin 100units/m 3-5mL, and/or 10mL sterile saline to access port a cath</li> </ul>		
Hydration: □ NS □ D5W	IV	Pre: ☐ 500mL ☐ 1000mL ☐ Other: Concurrent: ☐ 500mL ☐ 1000mL ☐ Other: (Not to be infused using the same access as Ig) Post: ☐ 500mL ☐ 1000mL ☐ Other:	Hydration max infusion ratemL/hr (Adult max rate 250mL/hr unless otherwise indicated)		
Diphenhydramine  ** For rash or hives (If oral, patient may be instructed to purchase from retail)	□ PO □ IV □ IM	25mg-50mg Peds: 1mg/kg Other:	☐ PRN mild/moderate allergic reaction ☐ Premed 30 minutes prior to infusion ☐ Initial dose (IV only): Administer 25 mg x 1 dose may repeat in 3-5 minutes if needed ☐ Subsequent doses: may repeat every 4-6 hours as needed (Adult max 100mg/day) ☐ Other:		
Acetaminophen  ** For aches, pain or fever (patient may purchase from retail)	РО	☐ 325mg-650mg ☐ Other:	☐ Premed 30 minutes prior to infusion ☐ May repeat every 4-6 hours as needed (Adult max 2000mg/day) ☐ Other:		
☐ Lido/Prilocaine 2.5%/2.5% ☐ Lidocaine 4%	TOP	30-60 grams	Apply to injection sites at least 1 hour before access Cover with occlusive dressing		
Epinephrine **home nursing requirement**	□ ІМ	☐ Adult 1:1000, 0.3mL (>30kg/>66lbs) ☐ Peds 1:2000, 0.3mL (15-30kg/33-66lbs) ☐ Infant 0.1mL/0.1mL, 0.1mL (7.5-15kg/16.5-33lbs)	PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed		
Additional Medication:					
	luents, pum	Other:  On 3 months Other:  On 4 months Other:  On 5 months Other:  On 5 months Other:  On 4 months Other:  On 5 months Other:  On 6 months Other:  On 7 months Other:	Ancillary supplies and kits provided as needed for administration		
DISPENSE AS WRITTEN		(Date) PRODUCT SUBSTITU			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. ©2019 CVS Pharmacy, Inc. or one of its affiliates. 75-35800A 040620